Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada
PaperCitations, authors & open-access status
A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 12 citations, 2022 year and gold oa status.
12
Citations
2022
Year
gold
OA Status